Procalcitonin has now been shown, in evolving descriptive studies, to be an additional valuable tool in the current COVID-19 pandemic to early identify patients at low risk for bacterial coinfection and adverse outcome.
PCT testing on admission seems to be a valuable additional piece of information to aid in early risk assessment and rule-out of bacterial coinfection in COVID-19 patients.
Monitoring of PCT was identified to be useful for detection of secondary infections and progression to more severe disease state like sepsis / septic shock.